Clinical Genome Sequencing

[1]  G. Proctor,et al.  Clinical assessment , 2014, BDJ.

[2]  R. Green,et al.  Personalized Genetic Risk Counseling to Motivate Diabetes Prevention , 2012, Diabetes Care.

[3]  Heather Skirton,et al.  Direct-to-consumer genomic testing: systematic review of the literature on user perspectives , 2012, European Journal of Human Genetics.

[4]  Heidi L. Rehm,et al.  Communicating new knowledge on previously reported genetic variants , 2012, Genetics in Medicine.

[5]  Robert C. Green,et al.  Exploring concordance and discordance for return of incidental findings from clinical sequencing , 2012, Genetics in Medicine.

[6]  Christopher A Cassa,et al.  Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. , 2012, Genome research.

[7]  I. Kohane,et al.  Taxonomizing, sizing, and overcoming the incidentalome , 2012, Genetics in Medicine.

[8]  E. Clayton,et al.  The legal risks of returning results of genomics research , 2012, Genetics in Medicine.

[9]  Stanley F. Nelson,et al.  DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study , 2012, Genetics in Medicine.

[10]  R. Sharp,et al.  The ethical hazards and programmatic challenges of genomic newborn screening. , 2012, JAMA.

[11]  Joan Scott,et al.  Risky Business: Risk Perception and the Use of Medical Services among Customers of DTC Personal Genetic Testing , 2012, Journal of Genetic Counseling.

[12]  Robert C. Green,et al.  Managing incidental findings and research results in genomic research involving biobanks and archived data sets , 2012, Genetics in Medicine.

[13]  G. Ginsburg,et al.  Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design , 2012, BMC Health Services Research.

[14]  J. Lupski,et al.  Human genome sequencing in health and disease. , 2012, Annual review of medicine.

[15]  P. Visscher,et al.  Five years of GWAS discovery. , 2012, American journal of human genetics.

[16]  Euan A Ashley,et al.  Performance comparison of whole-genome sequencing platforms , 2011, Nature Biotechnology.

[17]  J. Dungan,et al.  Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing , 2012 .

[18]  S. Werns.  Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial , 2012 .

[19]  J. Stockman.  HLA-A∗3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans , 2012 .

[20]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[21]  Jay Shendure,et al.  Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations , 2012, Nature Genetics.

[22]  R. Green,et al.  Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. , 2011, Genetic testing and molecular biomarkers.

[23]  S. Nelson,et al.  DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study , 2011, Genetics in Medicine.

[24]  R. Green,et al.  Design of a randomized trial of diabetes genetic risk testing to motivate behavior change: The Genetic Counseling/Lifestyle Change (GC/LC) Study for Diabetes Prevention , 2011, Clinical trials.

[25]  Barbara A Koenig,et al.  Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. , 2011, Mayo Clinic proceedings.

[26]  T. Miyata,et al.  Pharmacogenomics of clopidogrel: evidence and perspectives. , 2011, Thrombosis research.

[27]  M. Pirmohamed.  Pharmacogenetics: past, present and future. , 2011, Drug discovery today.

[28]  Christian Gilissen,et al.  Unlocking Mendelian disease using exome sequencing , 2011, Genome Biology.

[29]  G. Palomaki,et al.  Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. , 2011, JAMA.

[30]  C. Kobelka.  Sequencing: the next generation. Moving beyond population‐based recessive disease carrier screening , 2011, Clinical genetics.

[31]  R. Wilson,et al.  Modernizing Reference Genome Assemblies , 2011, PLoS biology.

[32]  R. Xavier,et al.  Genetics and pathogenesis of inflammatory bowel disease , 2011, Nature.

[33]  David R. Murdock,et al.  Whole-Genome Sequencing for Optimized Patient Management , 2011, Science Translational Medicine.

[34]  B. Bernhardt,et al.  Motivations and Perceptions of Early Adopters of Personalized Genomics: Perspectives from Research Participants , 2011, Public Health Genomics.

[35]  Muin J Khoury,et al.  Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time , 2011, Genetics in Medicine.

[36]  R. Green,et al.  The future of direct-to-consumer clinical genetic tests , 2011, Nature Reviews Genetics.

[37]  Guy A. Rouleau,et al.  The case for locus-specific databases , 2011, Nature Reviews Genetics.

[38]  Jeroen F. J. Laros,et al.  LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.

[39]  M. Pirmohamed,et al.  Aspirin resistance: effect of clinical, biochemical and genetic factors. , 2011, Pharmacology & therapeutics.

[40]  Elaine Lyon,et al.  The GeneInsight suite: a platform to support laboratory and provider use of DNA‐based genetic testing , 2011, Human mutation.

[41]  R. Green,et al.  Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk , 2011, Genetics in Medicine.

[42]  I. Moussa.  Coronary artery bifurcation interventions: The disconnect between randomized clinical trials and patient centered decision‐making , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[43]  David P Bick,et al.  Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease , 2011, Genetics in Medicine.

[44]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[45]  T. Marteau,et al.  Deflating the Genomic Bubble , 2011, Science.

[46]  Matthew S. Lebo,et al.  Development and validation of a computational method for assessment of missense variants in hypertrophic cardiomyopathy. , 2011, American journal of human genetics.

[47]  R. Sharp.  Downsizing genomic medicine: Approaching the ethical complexity of whole-genome sequencing by starting small , 2011, Genetics in Medicine.

[48]  N. Schork,et al.  Effect of direct-to-consumer genomewide profiling to assess disease risk. , 2011, The New England journal of medicine.

[49]  Michael R Stratton,et al.  Genomics and the continuum of cancer care. , 2011, The New England journal of medicine.

[50]  Isaac S. Kohane,et al.  Bioinformatics Applications Note Databases and Ontologies Automated Validation of Genetic Variants from Large Databases: Ensuring That Variant References Refer to the Same Genomic Locations , 2022 .

[51]  Yama W. L. Zheng,et al.  Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study , 2011, BMJ : British Medical Journal.

[52]  L. Garraway,et al.  Clinical implications of the cancer genome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Yama W. L. Zheng,et al.  Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus , 2010, Science Translational Medicine.

[54]  R. Green,et al.  The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study , 2010, European Journal of Human Genetics.

[55]  George Church,et al.  Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants: Updated Guidelines from a National Heart, Lung, and Blood Institute Working Group , 2010, Circulation. Cardiovascular genetics.

[56]  L. Bonello,et al.  Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism. , 2010, International journal of cardiology.

[57]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[58]  E. Antman,et al.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.

[59]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[60]  S. Paik,et al.  Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Heng Li,et al.  A survey of sequence alignment algorithms for next-generation sequencing , 2010, Briefings Bioinform..

[62]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[63]  Emily H Turner,et al.  Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome , 2010, Nature Genetics.

[64]  A. McGuire,et al.  The right to ignore genetic status of late onset genetic disease in the genomic era; Prenatal testing for Huntington disease as a paradigm , 2010, American journal of medical genetics. Part A.

[65]  K. Maclennan,et al.  Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens , 2010, Nucleic acids research.

[66]  R. Altman,et al.  Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. , 2010, The Lancet. Oncology.

[67]  Christian Gilissen,et al.  De novo mutations of SETBP1 cause Schinzel-Giedion syndrome , 2010, Nature Genetics.

[68]  H. Varmus.  Ten years on--the human genome and medicine. , 2010, The New England journal of medicine.

[69]  F. Collins,et al.  Genomic medicine--an updated primer. , 2010, The New England journal of medicine.

[70]  R. Green,et al.  Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. , 2010, The American journal of clinical nutrition.

[71]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[72]  P. Stankiewicz,et al.  Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. , 2010, The New England journal of medicine.

[73]  D. Hayes,et al.  Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  R. Green,et al.  “I know what you told me, but this is what I think:” Perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate , 2010, Genetics in Medicine.

[75]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[76]  Amy L. McGuire,et al.  Personalized genomic information: preparing for the future of genetic medicine , 2010, Nature Reviews Genetics.

[77]  K. Frazer,et al.  Microdroplet-based PCR amplification for large scale targeted sequencing , 2009, Nature Biotechnology.

[78]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[79]  P. Shannon,et al.  Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.

[80]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[81]  M. Pirmohamed.  Pharmacogenetics of idiosyncratic adverse drug reactions. , 2010, Handbook of experimental pharmacology.

[82]  R. Green,et al.  Genetic testing for Alzheimer's and long-term care insurance. , 2010, Health affairs.

[83]  P. Rinaldo,et al.  Newborn Screening in the Genomic Era : Setting a Research Agenda December , 2010 .

[84]  Robert Cook-Deegan,et al.  Disclosure of APOE genotype for risk of Alzheimer's disease. , 2009, The New England journal of medicine.

[85]  Juan P. Casas,et al.  Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies , 2009, PloS one.

[86]  G. Downing.  Key aspects of health system change on the path to personalized medicine. , 2009, Translational research : the journal of laboratory and clinical medicine.

[87]  Joseph Jozic,et al.  Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. , 2009, Translational research : the journal of laboratory and clinical medicine.

[88]  Jay Shendure,et al.  High-resolution analysis of DNA regulatory elements by synthetic saturation mutagenesis , 2009, Nature Biotechnology.

[89]  R. Green,et al.  Disclosing the Disclosure: Factors Associated With Communicating the Results of Genetic Susceptibility Testing for Alzheimer's Disease , 2009, Journal of health communication.

[90]  I. Tikhonova,et al.  Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.

[91]  H. White,et al.  Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. , 2009, JACC. Cardiovascular interventions.

[92]  Olivier Harismendy,et al.  Microdroplet-based Pcr enrichment for large-scale targeted sequencing , 2016 .

[93]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[94]  A. Rademaker,et al.  Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue , 2009, Genetics in Medicine.

[95]  Francisco M. De La Vega,et al.  Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. , 2009, Genome research.

[96]  Emily H Turner,et al.  Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.

[97]  R. Green,et al.  Direct to consumer genetic testing: Avoiding a culture war , 2009, Genetics in Medicine.

[98]  Daniel E Jonas,et al.  Genetic and clinical factors relating to warfarin dosing. , 2009, Trends in pharmacological sciences.

[99]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[100]  R. Cotton.  Collection of variation causing disease - The Human Variome Project , 2009, Human Genomics.

[101]  Tao Wang,et al.  Social Networkers' Attitudes Toward Direct-to-Consumer Personal Genome Testing , 2009, The American journal of bioethics : AJOB.

[102]  Xiaohua Huang,et al.  A device for automated hydrodynamic shearing of genomic DNA. , 2009, BioTechniques.

[103]  K. Bozic,et al.  Using observational data for decision analysis and economic analysis. , 2009, The Journal of bone and joint surgery. American volume.

[104]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[105]  A. Janssens,et al.  Genome-based prediction of common diseases: methodological considerations for future research , 2009, Genome Medicine.

[106]  Diana B Petitti,et al.  Update on the Methods of the U.S. Preventive Services Task Force: Insufficient Evidence , 2009, Annals of Internal Medicine.

[107]  P. Stenson,et al.  The Human Gene Mutation Database: 2008 update , 2009, Genome Medicine.

[108]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[109]  Karen L. Mohlke,et al.  Genetic Risk Prediction — Are We There Yet? , 2009 .

[110]  R. Tuckson.  Challenges and opportunities for evidence-based genetics practice , 2009, Genetics in Medicine.

[111]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[112]  R. Green,et al.  Perceptions of Familial Risk in those Seeking a Genetic Risk Assessment for Alzheimer’s Disease , 2009, Journal of Genetic Counseling.

[113]  Amy L. McGuire,et al.  An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. , 2008, JAMA.

[114]  Gail Geller,et al.  Public Expectations for Return of Results from Large-Cohort Genetic Research , 2008, The American journal of bioethics : AJOB.

[115]  Sara Chandros Hull,et al.  Patients' Views on Identifiability of Samples and Informed Consent for Genetic Research , 2008, The American journal of bioethics : AJOB.

[116]  Patrick L. Taylor.  Personal Genomes: When consent gets in the way , 2008, Nature.

[117]  Muin J. Khoury,et al.  The evidence dilemma in genomic medicine. , 2008, Health affairs.

[118]  Nancy F. Hansen,et al.  Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.

[119]  Scott T. Weiss,et al.  Creating and evaluating genetic tests predictive of drug response , 2008, Nature Reviews Drug Discovery.

[120]  Frances P Lawrenz,et al.  Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations , 2008, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

[121]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[122]  E. Mardis.  The impact of next-generation sequencing technology on genetics. , 2008, Trends in genetics : TIG.

[123]  R. Green,et al.  Health Behavior Changes After Genetic Risk Assessment for Alzheimer Disease: The REVEAL Study , 2008, Alzheimer disease and associated disorders.

[124]  G. Qiao,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .

[125]  R. Green,et al.  Incorporating ethnicity into genetic risk assessment for Alzheimer's disease: the REVEAL study , 2008 .

[126]  Christopher A Cassa,et al.  My sister's keeper?: genomic research and the identifiability of siblings , 2008, BMC Medical Genomics.

[127]  Jay Shendure,et al.  Multiplex amplification of large sets of human exons , 2007, Nature Methods.

[128]  G. Weinstock,et al.  Direct selection of human genomic loci by microarray hybridization , 2007, Nature Methods.

[129]  Kenneth D. Mandl,et al.  Reestablishing the Researcher-Patient Compact , 2007, Science.

[130]  Gynecologists.  ACOG Committee Opinion No. 360: Sex selection. , 2007, Obstetrics and gynecology.

[131]  R. Green,et al.  Recall of disclosed Apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: The REVEAL Study , 2006, Genetics in Medicine.

[132]  R. Altman,et al.  The incidentalome: a threat to genomic medicine. , 2006, JAMA.

[133]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[134]  S. Travis.  New thinking: theory vs practice. A case study illustrating evidence‐based therapeutic decision making , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[135]  M. Debiec‐Rychter,et al.  Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines , 2006, Pharmacology.

[136]  Jane Wilson.  To know or not to know? Genetic ignorance, autonomy and paternalism. , 2005, Bioethics.

[137]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[138]  P. Malpas.  The right to remain in ignorance about genetic information--can such a right be defended in the name of autonomy? , 2005, The New Zealand medical journal.

[139]  F. Miller,et al.  Disclosing individual results of clinical research: implications of respect for participants. , 2005, JAMA.

[140]  R. Green,et al.  Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. , 2005, Health affairs.

[141]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[142]  R. Green,et al.  Genetic susceptibility testing versus family history–based risk assessment: Impact on perceived risk of Alzheimer disease , 2005, Genetics in Medicine.

[143]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[144]  K. Offit,et al.  The "duty to warn" a patient's family members about hereditary disease risks. , 2004, JAMA.

[145]  Michel Eichelbaum,et al.  Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. , 2004, Pharmacogenetics.

[146]  R. Green,et al.  Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial , 2004, Genetics in Medicine.

[147]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[148]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[149]  Edwin W. Naylor,et al.  Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental Stress , 2003 .

[150]  F. Collins,et al.  Welcome to the genomic era. , 2003, The New England journal of medicine.

[151]  C. Lenfant.  Shattuck lecture--clinical research to clinical practice--lost in translation? , 2003, The New England journal of medicine.

[152]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[153]  R. Green,et al.  Reasons for Seeking Genetic Susceptibility Testing Among First‐Degree Relatives of People With Alzheimer Disease , 2003, Alzheimer disease and associated disorders.

[154]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[155]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[157]  J. Koziol,et al.  Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA , 2002, The Lancet.

[158]  W. Raut,et al.  Burkitt's lymphoma. , 2002, The Journal of the Association of Physicians of India.

[159]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[160]  P. Giampietro,et al.  Prevalence and patterns of presentation of genetic disorders in a pediatric emergency department. , 2001, Mayo Clinic proceedings.

[161]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[162]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[163]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[164]  T. Takala.  The right to genetic ignorance confirmed. , 1999, Bioethics.

[165]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[166]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[167]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[168]  J. Sheller,et al.  Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. , 1996, The Journal of pharmacology and experimental therapeutics.

[169]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[170]  M. Wein.  Duty to warn. , 1989, JAMA.

[171]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[172]  G. Sermonti.  The human genome. , 1988, Rivista di biologia.

[173]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[174]  J. Opitz,et al.  The effect of Mendelian disease on human health: a measurement. , 1985, American journal of medical genetics.

[175]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .